Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization

Badereddin Mohamad Al-Ali,Gero Kramer,Stephan Madersbacher,Ingrid Berger

Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization

2017

Badereddin Mohamad Al-Ali
Gero Kramer
Stephan Madersbacher
Ingrid Berger

Objective To analyze the drug adherence rates and overall survival for in patients treated with arbiraterone acetate (AA) for castration-resistant prostate cancer (CRPC).

Keywords:

Abiraterone
Abiraterone acetate
Prostate cancer
Urology
Castration
Medicine
in patient
Oncology
Internal medicine
castration resistant
Diabetes mellitus
overall survival
drug adherence

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations